Imperial College London
Portrait Picture

Dr Mark P. Lythgoe

Faculty of Medicine, Department of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

m.lythgoe

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Julve:2021:10.1080/14656566.2020.1828348,
author = {Julve, M and Lythgoe, M and Clark, J},
doi = {10.1080/14656566.2020.1828348},
journal = {Expert Opinion on Pharmacotherapy},
pages = {351--361},
title = {Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma},
url = {http://dx.doi.org/10.1080/14656566.2020.1828348},
volume = {22},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Despite the recent advances in the treatment of malignant melanoma with immunotherapy and BRAF/MEK targeted agents, advanced disease still beholds a poor prognosis for a significant proportion of patients. Cyclin dependent kinase (CDK) inhibitors have been investigated as novel melanoma therapeutics throughout a range of phase 1 and 2 trials, as single agents and in combination with established treatments.Areas covered: This article summarises the rationale for, and development of CDK inhibitors in melanoma, with their evolution from pan-CDK inhibitors to highly specific agents, throughout clinical trials and finally their potential future use.Expert opinion: Whilst CDK inhibitors have been practice changing in breast cancer management, their efficacy is yet to be proven in melanoma. Combination with BRAF/MEK inhibitors has been hindered by dose limiting toxicities, but their role may yet to be found within the spectrum of biomarker derived personalised melanoma management. The effect that CDK inhibitors can have as an adjunct to immunotherapy also remains to be seen.
AU  - Julve,M
AU  - Lythgoe,M
AU  - Clark,J
DO  - 10.1080/14656566.2020.1828348
EP  - 361
PY  - 2021///
SN  - 1465-6566
SP  - 351
TI  - Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
T2  - Expert Opinion on Pharmacotherapy
UR  - http://dx.doi.org/10.1080/14656566.2020.1828348
UR  - https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1828348
UR  - http://hdl.handle.net/10044/1/83813
VL  - 22
ER  -
Download